TradeFlare's AI research teams analysed MRNA on 16 market nights between July 2, 2026 and October 12, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.
| Date | Verdict | Price | Target / stop | 5 days later | 20 days later | Why (that night) |
|---|---|---|---|---|---|---|
| October 12, 2026 | HOLD | $225.00 | — / — | not yet | not yet | The current market regime and MRNA's price action suggest a need for caution and further observation rather than an immediate trade. |
| September 29, 2026 | HOLD | $197.28 | — / $167.69 | -7.9% | not yet | The current market regime and the stock's price state suggest a need for caution and a short-term outlook. |
| September 28, 2026 | HOLD | $198.88 | — / — | +3.0% | not yet | The current setup presents conflicting signals and high risk, necessitating a cautious approach. |
| September 25, 2026 | HOLD | $194.82 | $233.78 / $165.59 | -4.5% | not yet | The PEAD signal suggests potential for continued drift, but the conflicting fundamental and risk profiles necessitate a cautious approach. |
| September 24, 2026 | HOLD | $182.11 | — / — | -3.0% | not yet | The current setup does not warrant a BUY recommendation due to conflicting team signals and risk factors. |
| September 2, 2026 | HOLD | $154.27 | — / — | -9.4% | +25.3% | The current market regime and MRNA's internal team scores do not support a buy decision. |
| August 17, 2026 | BUY | $63.32 | — / — | +115.5% | +123.0% | FDA approval of mRNA flu vaccine (mFLUSIVA) provides a significant new revenue stream. |
| July 23, 2026 | BUY | $58.07 | — / — | +1.6% | +133.8% | The current market regime and MRNA's fundamental and technical outlook do not support a buy recommendation. |
| July 22, 2026 | BUY | $59.66 | — / — | -6.2% | +200.3% | Potential positive clinical trial data releases. |
| July 21, 2026 | HOLD | $59.49 | — / — | -6.5% | +5.5% | The current market and stock conditions do not present a clear trading opportunity. |
| July 20, 2026 | BUY | $61.82 | — / — | -6.5% | +8.3% | The stock is currently in a neutral market environment with strong bearish signals from both technical and fundamental teams, making a buy recommendation unwarranted. |
| July 17, 2026 | BUY | $63.15 | — / — | -12.5% | +2.4% | The current market regime and MRNA's fundamental and risk profiles do not support a buy recommendation. |
| July 7, 2026 | BUY | $79.76 | — / — | -15.5% | -28.6% | The current market regime and the stock's conflicting team scores do not support a new entry. |
| July 6, 2026 | BUY | $79.76 | — / — | -18.1% | -32.6% | The current market regime and the stock's conflicting team scores do not support a new entry. |
| July 3, 2026 | BUY | $79.76 | — / — | -18.1% | -32.6% | The scanner trigger suggests a short-term post-earnings drift, but the fundamental and risk profiles warrant caution. |
| July 2, 2026 | HOLD | $72.50 | — / — | -14.4% | -31.3% | Continued positive news sentiment driven by regulatory progress on flu vaccine. |
Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.